Author

K. Geng

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Assay:bulk RNA-seq· 3 Research Focus:cell type annotation· 2 Research Focus:drug response / drug discovery· 2 Organism:human· 2 Organism:mouse· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1

Frequent Co-Authors

C. Kutter· 3 shared A. Ortlieb· 1 shared A. Tannapfel· 1 shared A. Wiegard· 1 shared B. Hogberg· 1 shared C. Bay· 1 shared C. Sommerauer· 1 shared C. Teschendorf· 1 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 17 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

C. Kutter

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

CRISPR-Cas9-mediated genome engineering exaggerates genomic deletion at 10q23.31 including the PTEN gene locus mimicking cancer profiles

K. Geng, L. G. Merino, R. G. Veiga, C. Sommerauer, J. Epperlein, E. K. Brinkman, C. Kutter

This study identifies an unintended large genomic deletion at 10q23.31 in CRISPR-Cas9-modified HAP1 cells, which mimics cancer profiles and affects gene expression and histone modifications.

bioRxiv · Apr 5, 2023Cancer Biology

Co-inhibition of topoisomerase 1 and BRD4-mediated pause release selectively kills pancreatic cancer via readthrough transcription

D. P. Cameron, J. Grosser, S. Ladigan, V. Kuzin, E. Iliopoulou, A. Wiegard, H. Benredjem, S. T. Liffers, S. Lueong, P. F. Cheung, D. Vangala, M. Pohl, R. Viebahn, C. Teschendorf, H. Wolters, , L. Baranello

The paper shows that combining TOP1 and BRD4 inhibitors selectively kills pancreatic cancer cells by inducing readthrough transcription, without harming normal cells.

bioRxiv · Feb 10, 2023Cancer Biology

Nanoengineered DNA origami with repurposed TOP1 inhibitors targeting myeloid cells for the mitigation of neuroinflammation

K. Zhu, Y. Wang, H. Sarlus, K. Geng, E. Nutma, J. Sun, S.-Y. Kang, C. Bay, J. Han, H. Lund, S. Amor, J. Wang, X.-m. Zhang, C. Kutter, A. Ortlieb, , R. Harris

The paper identifies TOP1 inhibitors as therapeutic agents for neuroinflammation and develops a DNA origami nanosystem for targeted delivery to myeloid cells.

bioRxiv · Oct 4, 2021Immunology

Efficacy of Targeting SARS-CoV-2 by CAR-NK Cells

M. T. Ma, S. Badeti, K. Geng, D. Liu

This paper develops CR3022-CAR-NK cells to target SARS-CoV-2, showing they can bind viral proteins and kill infected cells in vitro.

bioRxiv · Aug 11, 2020 · PreprintImmunology